Does RUXOLITINIB Cause Hyperlipidaemia? 37 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Hyperlipidaemia have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.1% of all adverse event reports for RUXOLITINIB.
37
Reports of Hyperlipidaemia with RUXOLITINIB
0.1%
of all RUXOLITINIB reports
8
Deaths
17
Hospitalizations
How Dangerous Is Hyperlipidaemia From RUXOLITINIB?
Of the 37 reports, 8 (21.6%) resulted in death, 17 (45.9%) required hospitalization.
Is Hyperlipidaemia Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Hyperlipidaemia?
ALENDRONATE (511)
AMLODIPINE (226)
DENOSUMAB (204)
SITAGLIPTIN (186)
METHOTREXATE (184)
ROSUVASTATIN (179)
PREDNISONE (169)
FINASTERIDE (145)
MYCOPHENOLATE MOFETIL (141)
ASPIRIN (138)
Which RUXOLITINIB Alternatives Have Lower Hyperlipidaemia Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE